News & Updates

In the COSMIC-313 trial, the addition of the tyrosine kinase inhibitor (TKI) cabozantinib to the immune checkpoint inhibitor (ICI)-doublet regimen comprising nivolumab and ipilimumab (NIVO/IPI) improved progression-free survival (PFS) in patients with previously untreated, advanced renal-cell carcinoma (RCC) who had intermediate or poor prognostic risk according to the IMDC* category.

Perioperative nivolumab plus platinum-based chemotherapy improves pathological complete response (pCR) rate and survival outcomes vs neoadjuvant platinum-based chemotherapy alone in patients with resectable stage IIIA/B non-small-cell lung cancer (NSCLC), results of the NADIM II trial have shown.

In patients with coronary artery disease (CAD), augmenting their cardiac rehabilitation regimen with meditation may lead to improved quality of life (QoL), a study has shown.

Use of olmesartan in combination practice is safe and results in similar cardiovascular composite outcomes, including myocardial infarction (MI), when compared with active comparators in hypertensive patients who need more than two antihypertensive medications, reports a study.